Skip to content
Back to news

Servier steps up commitment to digital innovation for patients with Klineo partnership

Access to information on clinical trials can be complex and difficult for rare disease patients and their doctors. Klineo’s digital platform provides an accessible and intuitive tool that enables patients and/or referring specialists to quickly find suitable clinical trials in France. By means of a dedicated digital interface, patients can be informed in real time of therapeutic opportunities corresponding to their profile.

The aim of this partnership is to make information on currently available clinical trials more accessible, particularly in rare cancers where patient recruitment can pose a major challenge.

At this point, only Servier’s oncology clinical trials in France will be available on the platform. Once the initial feedback has been evaluated, the Group will consider rolling out the service to other countries.


*WeHealth by Servier is the expression of Servier’s digital health strategy, aimed at two key industry players: start-ups and incubators. It is part of a dynamic, open innovation ecosystem that focuses on developing various partnerships (co-development, licensing, strategic partnerships), drawing on the expertise of our teams around the world.